Abstract
Von Willebrand Factor (VWF) is a multimeric glycoprotein produced by endothelial cells, which increases in thrombogenicity especially under high shear rates. It bridges between vascular platelets and sub-endothelial collagen. There is abnormal VWF level in ischemic stroke patients, and VWF shows unique significance in valuing the prediction, treatment and prognosis of ischemic stroke. Numerous basic and clinical evidences suggest that VWF is a potential target for ischemic stroke treatment. In recent years, researches on VWF for prevention and treatment of ischemic stroke have been rapidly developed. The findings in this field are reviewed in this paper. Key words: Von Willebrand factor; Stroke; Targets
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
